drugset / Trial / NCT05781750
A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study was to assess the efficacy and safety of zetomipzomib (30 mg or 60 mg) compared with placebo in achieving renal response after 52 weeks of treatment in patients with active lupus nephritis (LN).
Timeline
- Start
- 2023-11-03
- Primary completion
- 2024-11-08
- Completion
- 2024-11-08
Outcome
Outcome not reported
Stopped (Business): “Sponsor Decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | zetomipzomib | Protein / enzyme biologic | 30 mg | Subcutaneous |
| Subject | zetomipzomib | Protein / enzyme biologic | 60 mg | Subcutaneous |